NASDAQ · Biotechnology

LXEO (LXEO) Stock

$4.35 +0.93% NASDAQ: LXEO Healthcare

Valuation

MetricValue
Price$4.35
Market Cap$341.57M
P/E Ratio-2.48
P/B Ratio1.46
P/S Ratio0.00
EPS (TTM)$-1.86
52-Week High$10.99
52-Week Low$3.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-40.49%
ROA-37.17%
ROCE-44.13%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.03
Current Ratio11.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$1.0M$0$0$0
Operating Profit$-51.0M$-61.0M$-69.0M$-106.0M$-109.0M
Net Profit$-51.0M$-59.0M$-66.0M$-98.0M$-100.0M
EPS$-2.01$-2.40$-2.49$-3.09$-1.86
Op Margin-3055.9%-9252.1%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$137.0M$97.0M$140.0M$147.0M$269.0M
Total Liabilities$192.0M$210.0M$26.0M$30.0M$22.0M
Cash$136.0M$77.0M$121.0M$35.0M$63.0M
Borrowings$0$13.0M$12.0M$10.0M$8.0M

Latest News

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple Insider Monkey · Jul 15, 2026 Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? Insider Monkey · Jul 2, 2026 Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia GlobeNewswire · Jun 17, 2026 Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy MT Newswires · Jun 15, 2026 Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia GlobeNewswire · Jun 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-44.0M$-55.0M$-59.0M$-81.0M$-99.0M
Investing Cash Flow$0$-2.0M$0$-95.0M$-91.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$106.0M$-55.0M$44.0M$-86.0M$28.0M
Free Cash Flow$-44.0M$-55.0M$-60.0M$-82.0M$-99.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-26.42%
Quick Ratio14.16
Interest Coverage—
Return 1Y20.77%
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.60%
Institutions Held114.52%
Institutions Float Held115.22%
Institutional HolderSharesReport Date
Paradigm Biocapital Advisors LP6,184,1342026-03-31
Blackrock Inc.5,110,8712026-03-31
Affinity Asset Advisors, Llc5,050,2112026-03-31
RA Capital Management, L.P.5,000,0002026-03-31
Janus Henderson Group PLC4,976,4292026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
CAPR $3.93 -5.76% -50.70 $227.59M 0.00%
CTNM $14.16 +2.16% -6.62 $529.39M 0.00%
DBVTDBV Technologies S.A. $15.84 +0.83% -3.27 $378.92M 0.00%
KYTX $7.30 -2.54% -2.49 $443.81M 0.00%

About LXEO

LXEO is led by CEO R. Nolan Townsend, employs 75 people, headquartered in US, publicly traded since 2023.

LXEO stock trades at $4.35 with a market capitalization of $341.57M. The stock is valued at a price-to-earnings (P/E) ratio of -2.48, price-to-book of 1.46, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.60 and $10.99, and currently trades 60.4% below its 52-week high.

On profitability, LXEO generates a return on equity (ROE) of -40.49%, return on capital employed of -44.13%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides